Orthofix Cervical-Stim PMA Filing Almost Complete; Firm Settles With TriCare
This article was originally published in The Gray Sheet
Executive Summary
Regulations governing TriCare coverage policies do not prohibit reimbursement of FDA-approved products for off-label uses, Orthofix maintains, despite paying $1.7 mil. in a billing investigation settlement with the Department of Justice
You may also be interested in...
Orthofix’ $150 Mil. Breg Purchase Will Produce PoC “Gatekeeper” – CEO
Orthofix will gain access to Breg Inc.'s sales and distribution relationships with general orthopedic offices as part of a $150 mil. acquisition to expand into spinal, reconstruction and trauma orthopedic franchises
Orthofix’ $150 Mil. Breg Purchase Will Produce PoC “Gatekeeper” – CEO
Orthofix will gain access to Breg Inc.'s sales and distribution relationships with general orthopedic offices as part of a $150 mil. acquisition to expand into spinal, reconstruction and trauma orthopedic franchises
Improper Device Reimbursement Coding Focus Of Federal Scrutiny – Attorneys
Device companies should be wary of reimbursement consultants engaged in "up-coding" - or increasing reimbursement rates by manipulating existing codes - as the government increasingly turns its attention to investigating device fraud